Mikiya Ishihara, Yoshihiro Nishida, Shigehisa Kitano, Akira Kawai, Naozumi Harada, Yoshihiro Miyahara, Hiroyoshi Hattori, Kohichi Takada, Makoto Emori, Shigeki Kakunaga, et al. O16-2 Phase I trial of NY-ESO-1 TCR-T cell therapy combined with nanoparticulate vaccine but without lymphodepletion for STS. Annals of Oncology. 2023. 34. S1391-S1391
Akira Tsunoda, Koshi Sukeno, Hiroki Oka, Yasutaka Tono, Mikiya Ishihara, Kanako Saito, Satoshi Tamaru, Yoshiki Yamashita, Toshiro Mizuno, Isao Tawara. P40-3 Retrospective analysis of amrubicin therapy for advanced or recurrent neuroendocrine carcinoma in our facility. Annals of Oncology. 2023. 34. S1456-S1456
Yasutaka Tono, Koushi Sukeno, Akira Tsunoda, Hiroki Oka, Mikiya Ishihara, Kanako Saito, Satoshi Tamaru, Yoshiki Yamashita, Takumi Fujiwara, Takahito Kitajima, et al. MO36-3 Clinical management of cancer of unknown primary with unfavorable subset: A retrospective analysis. Annals of Oncology. 2023. 34. S1419-S1419
Mitsuo Terada, Aki Ito, Yuichiro Kikawa, Kei Koizumi, Yoichi Naito, Tatsunori Shimoi, Mikiya Ishihara, Takashi Yamanaka, Yukinori Ozaki, Fumikata Hara, et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition. Breast cancer (Tokyo, Japan). 2023. 30. 6. 872-884
Manabu Futamura, Takahiro Nakayama, Tetsuhiro Yoshinami, Chiya Oshiro, Mikiya Ishihara, Midori Morita, Akira Watanabe, Azusa Tanigichi, Masami Tsukabe, Masafumi Shimoda, et al. Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316). Breast cancer (Tokyo, Japan). 2023. 30. 6. 943-951
A novel affinity-enhanced NY-ESO-1-targeting TCR-redirected T cell transfer exhibited early-onset cytokine release syndrome and subsequent tumor responses in synovial sarcoma patients
(ESMO 2019 2019)
PCR法によるMAGE-A4、NY-ESO-1およびSAGE抗原の腫瘍組織における発現(MAGE-A4, NY-ESO-1 and SAGE expression in tumor samples assessed by RT-PCR)
(日本癌学会総会記事 2019)